Xeris Biopharma Enters Into an Exclusive Worldwide License Agreement for Xeriject® Formulation of Teprotumumab
- None.
- None.
Insights
The licensing agreement between Xeris Biopharma Holdings and Amgen marks a pivotal step in the commercialization strategy for Xeris. The deal leverages Xeris' proprietary XeriJect® technology to enhance the delivery of teprotumumab, potentially improving patient adherence and outcomes in Thyroid Eye Disease (TED) treatment. The financial terms, including $75 million in development and regulatory milestones, sales-based milestones and royalties, suggest a strong validation of Xeris' technology and a significant revenue stream contingent on successful development and market penetration. The deal's structure is typical for the industry, where upfront payments and milestones are coupled with royalties to balance risk and reward between the licensor and licensee.
Exclusive worldwide licensing agreements are a common strategic tool in biopharma for accessing innovative technologies that can expedite drug development and enhance drug delivery. Xeris' XeriJect® technology represents a proprietary platform that enables subcutaneous injection of large molecules, which traditionally might require intravenous administration. This can be a game-changer in terms of patient convenience and compliance, particularly for chronic conditions like TED that require ongoing treatment. The licensing deal not only provides Amgen with a competitive edge in TED therapy but also sets a precedent for future licensing opportunities for Xeris with other large molecule therapies.
Thyroid Eye Disease is a rare autoimmune condition with a limited patient population, which typically translates into a high-value market due to the lack of effective treatments. Teprotumumab, known as TEPEZZA® in the U.S., is already a significant player in this niche market. The agreement to develop a subcutaneous formulation using Xeris’ technology could potentially expand the drug's market share by offering a more patient-friendly administration route. This could lead to increased demand and higher sales, benefiting both Xeris and Amgen. However, the success of this agreement is contingent on the clinical and commercial success of the new formulation, which poses inherent risks associated with drug development and market acceptance.
“We are very excited that our partner is moving forward with licensing the XeriJect technology to further the development of the XeriJect subcutaneous teprotumumab to potentially enhance the patient experience and delivery of the treatment for Thyroid Eye Disease. This agreement to license XeriJect further validates the potential value of our technology to enable large molecule subcutaneous injections that provide a more patient friendly regimen that is effective, safe, and more convenient, with potential for improved adherence,” said Paul R. Edick, Chairman and CEO of Xeris. “We will move quickly to support our partner in this important development program.”
Under the terms of the License Agreement, Xeris has the potential to receive
About XeriJect®
XeriJect formulations are innovative, ready-to-use, viscoelastic pharmaceutical suspensions that have the potential to improve drug delivery, lower treatment burden and improve patients' lives across a broad range of therapeutic categories. XeriJect suspensions maximize drug loadings at >400mg/mL, enable small volume subcutaneous injections and do not settle on storage. The suspensions use FDA-approved excipients and leverage known manufacturing processes. XeriJect formulation technology is well suited for drugs and biologics including large molecules such as proteins, monoclonal antibodies, and vaccines. The technology is protected by an extensive patent estate, trade secrets and know-how, and it is available for licensing.
About Xeris
Xeris (Nasdaq: XERS) is a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies. Xeris has three commercially available products; Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis®, for a proven therapy for primary periodic paralysis, and Recorlev® for the treatment of endogenous Cushing’s syndrome. Xeris also has a robust pipeline of development programs to extend the current marketed products into important new indications and uses and bring new products forward using its proprietary formulation technology platforms, XeriSol™ and XeriJect®, supporting long-term product development and commercial success.
Xeris Biopharma Holdings is headquartered in
Forward-Looking Statements
Any statements in this press release other than statements of historical fact are forward-looking statements. Forward-looking statements include, but are not limited to, statements about future expectations, plans and prospects for Xeris Biopharma Holdings, Inc., including the development and potential of XeriJect® subcutaneous TEPEZZA®, the expectations regarding future product development efforts between Xeris and Amgen, Xeris’ potential entitlements to milestone and royalty payments from Amgen, the potential utility of its formulation platforms such as XeriJect, the market and therapeutic potential of its products and product candidates, and other statements containing the words “will,” “would,” “continue,” “expect,” “should,” “anticipate” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on numerous assumptions and assessments made in light of Xeris’ experience and perception of historical trends, current conditions, business strategies, operating environment, future developments, geopolitical factors and other factors it believes appropriate. By their nature, forward-looking statements involve known and unknown risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. The various factors that could cause Xeris’ actual results, performance or achievements, industry results and developments to differ materially from those expressed in or implied by such forward-looking statements, include, but are not limited to, its financial position and need for financing, including to fund its product development programs or commercialization efforts, whether its products will achieve and maintain market acceptance in a competitive business environment, its reliance on third-party suppliers, including single-source suppliers, its reliance on third parties to conduct clinical trials, the ability of its product candidates to compete successfully with existing and new drugs, and its and collaborators’ ability to protect its intellectual property and proprietary technology. No assurance can be given that such expectations will be realized and persons reading this communication are, therefore, cautioned not to place undue reliance on these forward-looking statements. Additional risks and information about potential impacts of financial, operational, economic, competitive, regulatory, governmental, technological, and other factors that may affect Xeris can be found in Xeris’ filings, including its most recently filed Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission, the contents of which are not incorporated by reference into, nor do they form part of, this communication. Forward-looking statements in this communication are based on information available to us, as of the date of this communication and, while we believe our assumptions are reasonable, actual results may differ materially. Subject to any obligations under applicable law, we do not undertake any obligation to update any forward-looking statement whether as a result of new information, future developments or otherwise, or to conform any forward-looking statement to actual results, future events, or to changes in expectations.
About TEPEZZA
INDICATION
TEPEZZA is indicated for the treatment of Thyroid Eye Disease regardless of Thyroid Eye Disease activity or duration.
IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
Infusion Reactions: TEPEZZA may cause infusion reactions. Infusion reactions have been reported in approximately
Preexisting Inflammatory Bowel Disease: TEPEZZA may cause an exacerbation of preexisting inflammatory bowel disease (IBD). Monitor patients with IBD for flare of disease. If IBD exacerbation is suspected, consider discontinuation of TEPEZZA.
Hyperglycemia: Increased blood glucose or hyperglycemia may occur in patients treated with TEPEZZA. In clinical trials,
Hearing Impairment Including Hearing Loss: TEPEZZA may cause severe hearing impairment including hearing loss, which in some cases may be permanent. Assess patients’ hearing before, during, and after treatment with TEPEZZA and consider the benefit-risk of treatment with patients.
ADVERSE REACTIONS
The most common adverse reactions (incidence ≥
Please see Full Prescribing Information or visit TEPEZZAhcp.com for more information.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240109335095/en/
Allison Wey
Senior Vice President, Investor Relations and Corporate Communications
awey@xerispharma.com
Source: Xeris Biopharma Holdings, Inc.
FAQ
What is the exclusive worldwide license agreement Xeris Biopharma has entered into?
What is the potential payment under the License Agreement?
What is TEPEZZA known as in the United States?
